Rivaroxaban in Left Ventricular Thrombus

Phase 3

Recruiting

• Conditions: Pre-acute ST-segment Elevation Myocardial Infarction (STEMI) Left Ventricular (LV) thrombosis.; Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction; I23.6

• Registration Number: IRCT20181022041406N4
• Lead Sponsor: Rajaie cardiovascular medical and research center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

All patients with the age of 18-80 admitted with an acute STEMI
Presence of LV thrombosis, which were confirmed by transthrocic echocardiography
Signed informed consent

Exclusion Criteria

Previous history of mechanical prosthetic heart valve
Candidate for coronary artery bypass graft surgery
Active bleeding
Cardiogenic shock
Acute Kidney Injury or Chronic Kidney Disease with a glomerular filtration rate <30 ml/min
Liver failure (Child-Pugh class C)
Sensitivity or intolerance to rivaroxaban/warfarin/P2Y12 inhibitors

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Resolution of left ventricular thrombus. Timepoint: 3 months after initiation of antithrombotic therapeutic regimen. Method of measurement: Transthoracic echocardiography.

Secondary Outcome Measures

Name	Time	Method
Bleeding after initiation of antithrombotic regimen. Timepoint: 1 month and 3 months after initiation of antithrombotic regimen. Method of measurement: ISTH criteria.